Pharma's good times are here, GlobalData revenue analysis shows

7 September 2022

It is no secret that last year was a generally a positive one for the world’s largest biopharmaceutical companies, particularly those with COVID-19 vaccines.

But just how good it was has now been revealed by GlobalData, the data and analytics company, in analysis showing that, in 2021, the top 20 firms had an aggregate revenue of $846.8 billion and a growth of $166.4 billion over 2020.

But perhaps most telling is the finding that 13 of the top 20 players reported more than 10% year on-year (YoY) revenue growth from 2020 to 2021. Remarkably, as many as four reported YoY revenue growth in excess of 80%. These were BioNTech (Nasdaq: BNTX), Moderna (Nasdaq: MRNA), Pfizer (NYSE: PFE) and Regeneron Pharmaceuticals (Nasdaq: REGN).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK